FBRX earnings date and last-quarter result: next report 2026-08-13, last quarter miss, P/E -12.36. Updated 2026-07-23.
Forte Biosciences (FBRX) Research Hub
Forte Biosciences (FBRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-08-28, shares last closed at 76.99 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.36, market cap 0.70B. This hub links to the full technical, earnings and options research available for FBRX.
Last updated 2026-08-28 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 76.99 USD (0.00%) |
| 52-week range | 17.17 USD – 77.2 USD |
| Trend regime | Range |
| 14-day RSI | 61.2 (Bullish) |
| Trailing P/E | -12.36 |
| Market cap | 0.70B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for FBRX
Covered Call on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on FBRX: how it works, illustrative setup around the real 76.99 USD price, max profit/loss, breakeven and when to use it. Educational.
FBRX technical analysis: range, last 76.99 USD, RSI 61.2, 52w range 17.17 USD–77.2 USD, real support/resistance. Updated 2026-08-28.
More on SniperIQ
Frequently asked questions
What sector is FBRX in?
Forte Biosciences (FBRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is FBRX in an uptrend or downtrend?
As of 2026-08-28, FBRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is FBRX's trailing P/E ratio?
FBRX's trailing P/E is -12.36, with a market cap of 0.70B. See the earnings research page for full valuation detail.
When does FBRX next report earnings?
FBRX is next scheduled to report earnings on 2026-08-13.